List of works by Marco Fiorillo

"Energetic" Cancer Stem Cells (e-CSCs): A New Hyper-Metabolic and Proliferative Tumor Cell Phenotype, Driven by Mitochondrial Energy

A mitochondrial based oncology platform for targeting cancer stem cells (CSCs): MITO-ONC-RX

scholarly article by Federica Sotgia published in September 2018

Bedaquiline, an FDA-approved antibiotic, inhibits mitochondrial function and potently blocks the proliferative expansion of stem-like cancer cells (CSCs).

scientific article published on 22 June 2016

Doxycycline down-regulates DNA-PK and radiosensitizes tumor initiating cells: Implications for more effective radiation therapy

scientific article

Doxycycline, Azithromycin and Vitamin C (DAV): A potent combination therapy for targeting mitochondria and eradicating cancer stem cells (CSCs)

Estrogen related receptor α (ERRα) a promising target for the therapy of adrenocortical carcinoma (ACC)

scientific article

Graphene oxide selectively targets cancer stem cells, across multiple tumor types: implications for non-toxic cancer treatment, via "differentiation-based nano-therapy".

scientific article published on February 2015

Hallmarks of the cancer cell of origin: Comparisons with "energetic" cancer stem cells (e-CSCs)

Mitochondrial "power" drives tamoxifen resistance: NQO1 and GCLC are new therapeutic targets in breast cancer

scientific article

Mitochondrial biogenesis is required for the anchorage-independent survival and propagation of stem-like cancer cells

scientific article

Mitochondrial markers predict recurrence, metastasis and tamoxifen-resistance in breast cancer patients: Early detection of treatment failure with companion diagnostics

scientific article published on 27 July 2017

Mitoriboscins: Mitochondrial-based therapeutics targeting cancer stem cells (CSCs), bacteria and pathogenic yeast ⬇️

scientific article published on 7 July 2017

Repurposing atovaquone: targeting mitochondrial complex III and OXPHOS to eradicate cancer stem cells

scientific article published on 30 April 2016

The ER-alpha mutation Y537S confers Tamoxifen-resistance via enhanced mitochondrial metabolism, glycolysis and Rho-GDI/PTEN signaling: Implicating TIGAR in somatic resistance to endocrine therapy

Paulina is supported by:

About Paulina

Help